Ray Dalio Neogenomics Inc Transaction History
Bridgewater Associates, LP
- $17.3 Billion
- Q3 2024
A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Neogenomics Inc stock. As of the latest transaction made, Bridgewater Associates, LP holds 50,354 shares of NEO stock, worth $906,372. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,354
Previous 62,728
19.73%
Holding current value
$906,372
Previous $870,000
14.71%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding NEO
# of Institutions
295Shares Held
125MCall Options Held
698KPut Options Held
120K-
Black Rock Inc. New York, NY19.7MShares$354 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA14MShares$253 Million0.0% of portfolio
-
Brown Advisory Inc6.89MShares$124 Million0.13% of portfolio
-
Janus Henderson Group PLC London, X06.6MShares$119 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.54MShares$118 Million0.06% of portfolio
About NEOGENOMICS INC
- Ticker NEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 125,796,000
- Market Cap $2.26B
- Description
- NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...